First New York Securities’s BioMarin Pharmaceuticals BMRN Stock Holding History

First New York Securities’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-2,000	Closed	-$249K	–	452
2015 Q1	$249K	Buy	+2,000	New	+$212K	0.25%	55
2014 Q4	–	Sell	-500	Closed	-$36.1K	–	374
2014 Q3	$36.1K	Sell	500 -32,109	-98%	-$2.11M	0.03%	286
2014 Q2	$2.03M	Buy	+32,609	New	+$1.97M	2.09%	9
2013 Q3	–	Sell	-7,000	Closed	-$390K	–	358
2013 Q2	$390K	Buy	+7,000	New	+$436K	0.15%	120

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

First New York Securities's BMRN Position: Q2 2015 in Review

First New York Securities sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2015, closing a stake of 2,000 shares — an estimated $249K sold.

First New York Securities first reported a position in BMRN in Q2 2013 and held it in 4 quarters. The position peaked at $2.03M in Q2 2014. 392 funds tracked by Wall St. Rank hold BMRN as of Q2 2015.

First New York Securities reported no remaining BioMarin Pharmaceuticals position as of Q2 2015 after selling out during the quarter.
First New York Securities sold 2,000 BioMarin Pharmaceuticals shares in Q2 2015, an estimated $249K.
First New York Securities first reported a position in BioMarin Pharmaceuticals in Q2 2013 and held it in 4 quarters.
First New York Securities's BioMarin Pharmaceuticals position peaked at $2.03M in Q2 2014.
392 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2015.

Based on First New York Securities's 13F filing for Q2 2015, filed 30 Jul 2015.